Upstream Bio's Verekitug Demonstrates Positive Phase 2 Efficacy in Severe Asthma

Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, an investigational drug for severe asthma. The treatment significantly reduced annualized asthma exacerbation rates by 56% and improved lung function compared to placebo. This development is significant for patients with severe asthma, as the company plans to advance verekitug into Phase 3 trials in Q1 2027 for severe asthma and chronic rhinosinusitis with nasal polyps.